Similar Posts
May 2015 : Innokeys Pte Ltd at Asia Biotech Invest 2015
ByInnokeysKowloon, Hong Kong (May 20, 2015) – Innokeys Pte Ltd attended the Asia Biotech Invest 2015 as one of the presenting companies….
July 2015: Innokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG
ByInnokeysInnokeys Pte Ltd Consolidates Nimotuzumab Development by Acquiring Oncoscience AG • The acquisition enables Innokeys to fully lead clinical and commercial development…
August 2013: Nimotuzumab in MOGA Australia
ByInnokeysMedical Oncology Group of Australia
New Marketing Authorization Approval in The Philippines for new indication of locally advanced unresectable or metastatic pancreatic cancer.
ByInnokeysOn 18 Sep 2020, Philippines FDA approved new marketing authorization for indication locally advanced unresectable or metastatic pancreatic cancer for nimotuzumab. This…
August 2015: Innokeys Pte Ltd attends Congress of Obstetrics and Gynecology Indonesia 2015
ByInnokeysInnokeys Pte Ltd attends Congress of Obstetrics and Gynecology Indonesia 2015 Bandung, Indonesia (Augus 26, 2015) – Innokeys Pte Ltd attended the…
Webinar – Treatment Optimization in Locally Advanced & Metastatic Pancreatic Cancer-Tailored Patient Approach with Targeted Therapy
ByInnokeysProf. Dr. Dirk Strumberg, Oncologist in Marien Hospital Herne, Germany